Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain
Status:
Withdrawn
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the efficacy of ATNC05 in the treatment of Atypical
Facial Pain (AFP), also known as Persistent Idiopathic Facial Pain (PIFP). This research
project targets patients with chronic constant facial pain and excludes patients with
primarily paroxysmal pain.